Senior safety insights & evidence lead
ZürichArgenx
...lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of g MG, and with the potential to treat patients across dozens of severe autoimmune [...]
Kategorie Handel